Literature DB >> 3592385

Effect of prostaglandin E1 on the periosteal regional acceleratory phenomenon in fractured ribs: histomorphometric study in beagles.

M S Shih, R W Norrdin.   

Abstract

Transverse fractures were made surgically in the midshaft of the left 9th and 10th ribs in adult Beagles. A buffer vehicle (n = 4) or 0.2 mg of prostaglandin (PG) E1/day (n = 6) was injected into the fracture sites twice a day for 10 days, and dogs were euthanatized on day 30. Double-pulsed fluorescent labels were given with each of 2 fluorochrome markers--calcein before surgical treatment and oxytetracycline HCl before euthanasia. Histomorphometric analysis was carried out on specimens collected in adjacent regions of the healing defects. The surface extent and width of the osteoid on fractured (P less than 0.01, P less than 0.05, respectively) and nonfractured (P less than 0.05) sites in the treated group were greater than those in the nontreated group. The net loss of mineralizing surfaces was noticed on both ribs of both groups. Of 11 samples on the fractured side in the treated group, 4 contained periosteal new bone proliferation. There was increased osteoid formation and decreased mineralizing surfaces in the PGE1-treated group. Seemingly, administration of PGE1 induced bone matrix formation on periosteal envelope adjacent to a fracture site and its contralateral matching site.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3592385

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  2 in total

1.  Case report 701: Prostaglandin E1 (PGE1) periostitis.

Authors:  R F Rowley; J P Lawson
Journal:  Skeletal Radiol       Date:  1991       Impact factor: 2.199

2.  Effects of prostaglandin E1 on callus formation in rabbits.

Authors:  Pawel V Lipinsky; Ivan V Sirotin; Alexandr V Skoroglyadov; Alexey V Ivkov; Alexandr P Oettinger; Evgeny E Krynetskiy; Alexandr B But-Gusaim; Andreas J Roth
Journal:  BMC Musculoskelet Disord       Date:  2015-09-10       Impact factor: 2.362

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.